论文部分内容阅读
[目的]观察甲睾酮联合米非司酮治疗围绝经期子宫肌瘤的临床疗效。[方法]将60例围绝经期子宫肌瘤的患者随机分为治疗组和对照组,对照组给予口服米非司酮治疗,治疗组在对照组的基础上加服甲睾酮。3个月为1个疗程,连服2个疗程。6个月后随访月经及肌瘤变化情况,评价临床疗效。[结果]经治疗2个疗程后,治疗组临床疗效总有效率(96.7%)高于对照组(80.0%),两组比较差异有统计学意义(P﹤0.05);两组治疗前后子宫和肌瘤的体积比较,差异均有统计学意义(P﹤0.05),说明两组均有缩瘤的作用;治疗后组间比较,差异无统计学意义(P﹥0.05),随访观察治疗组在诱导绝经及缩瘤的疗效稳定性方面优于对照组(P﹤0.05)。[结论]甲睾酮联合米非司酮能有效治疗围绝经期子宫肌瘤。
[Objective] To observe the clinical efficacy of methyltestosterone combined with mifepristone in the treatment of perimenopausal uterine fibroids. [Method] 60 cases of menopausal uterine fibroids were randomly divided into treatment group and control group. The control group was treated with mifepristone. The treatment group was given methyltestosterone on the basis of the control group. 3 months for a course of treatment, and even served 2 courses. Six months after follow-up menstrual and fibroid changes, evaluation of clinical efficacy. [Results] After two courses of treatment, the total effective rate (96.7%) in the treatment group was higher than that in the control group (80.0%), the difference was statistically significant (P <0.05) The volume of fibroids, the difference was statistically significant (P <0.05), indicating that both groups have the role of tumor shrinking; after treatment, the difference was not statistically significant (P> 0.05) Induced menopause and tumor shrinkage of the efficacy and stability than the control group (P <0.05). [Conclusion] Methyltestosterone combined with mifepristone can effectively treat uterine fibroids in menopause.